Share chart Intra-Cellular Therapies, Inc.
Main settings
Grade
Underestimation
| Title | Value | Grade |
| P/S | 12.65 | 1 |
| P/BV | 7.5 | 1 |
| P/E | -182.12 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -7.13 | 0 |
| ROE | -8.58 | 0 |
| ROIC | -41.78 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.1455 | 10 |
| Debt/Ratio | 0.0124 | 10 |
| Debt/Equity | 0.1902 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | 2926.01 | 10 |
| Ebitda, % | -49.52 | 0 |
| EPS, % | -77.58 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 131.87 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 131.87 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Month | 131.87 $ | 131.87 $ | 131.87 $ | 0 % | 0 % | 0 % |
| Three month | 131.87 $ | 131.87 $ | 131.87 $ | 0 % | 0 % | 0 % |
| Half a year | 131.81 $ | 131.87 $ | 131.87 $ | +0.0455 % | 0 % | 0 % |
| Year | 73.88 $ | 73.24 $ | 131.92 $ | +78.49 % | 0 % | 0 % |
| 3 years | 39.8 $ | 43.8 $ | 131.92 $ | +231.33 % | 0 % | 0 % |
| 5 years | 12.6 $ | 23.34 $ | 131.92 $ | +946.59 % | 0 % | 0 % |
| 10 years | 7.5 $ | 7.5 $ | 131.92 $ | +1 756 % | 0 % | 0 % |
| Year to date | 86.72 $ | 81.78 $ | 131.92 $ | +52.06 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| PSYK ETF | 6.54 | 0 | 0.75 |
| Future Tech ETF | 0.79497 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.79497 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.32477 | 529.83 | 0.06 |
| Fidelity Growth Opportunities ETF | 0.24923 | -18.43 | 0.38 |
| iShares Morningstar Small-Cap ETF | 0.16384 | 293.87 | 0.25 |
| 1.47 | 213.47 | 0.36 |
|---|
Similar companies
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Michael I. Halstead J.D. | President | 983.65k | 1973 (52 years) |
| Dr. Suresh K. Durgam M.D. | Executive VP & Chief Medical Officer | 961.84k | 1969 (56 years) |
| Mr. Mark Neumann | EVP & Chief Commercial Officer | 998.36k | 1963 (62 years) |
| Mr. Juan Fernando Sanchez | Vice President of Corporate Communications & Investor Relations | 296.75k | 1971 (54 years) |
| Ms. Karen Patruno Sheehy Esq. | Senior VP & Chief Compliance Officer | N/A | 1962 (63 years) |
| Dr. Michael Olchaskey | Senior VP & Head of Regulatory Affairs | N/A | |
| Mr. John A. Bardi | Senior VP of Market Access, Policy & Government Affairs | N/A | |
| Dr. Robert E. Davis Ph.D. | Senior VP & Chief Scientific Officer | 646.12k | 1951 (74 years) |
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & CEO | 2.23M | 1953 (72 years) |
| John P. Condon | Senior Vice President, General Counsel & Secretary |
About company
Website: https://www.intracellulartherapies.com
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., биофармацевтическая компания, разрабатывает новые препараты для лечения психоневрологических и неврологических заболеваний и других заболеваний центральной нервной системы (ЦНС) в США. Компания разрабатывает свой ведущий кандидат на лекарство CAPLYTA для лечения шизофрении, биполярного расстройства, поведенческих нарушений, связанных с деменцией, аутизмом и другими заболеваниями ЦНС. Также разрабатывается ITI-002, который ингибирует фермент фосфодиэстеразу типа 1; ITI-214 для болезни Паркинсона; и ITI-333 для расстройств, связанных с употреблением психоактивных веществ, боли и сопутствующих психических заболеваний, включая депрессию и тревогу. Головной офис Intra-Cellular Therapies, Inc. находится в Нью-Йорке, штат Нью-Йорк.
